These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34556309)

  • 21. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teprotumumab for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2020; 60(2):47-55. PubMed ID: 32205652
    [No Abstract]   [Full Text] [Related]  

  • 23. Rifle Blast Exacerbating Hearing Loss in a Patient Treated With Teprotumumab for Thyroid Eye Disease.
    Reed DS; Kostosky N; Davies BW; Epstein A; Durairaj VD
    Ophthalmic Plast Reconstr Surg; 2022 Mar-Apr 01; 38(2):e41-e43. PubMed ID: 34652314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Teprotumumab vs Intravenous Methylprednisolone for Thyroid Eye Disease: Is There Still a Role for Steroids?
    Campbell AA
    JAMA Ophthalmol; 2022 Apr; 140(4):335-336. PubMed ID: 35175298
    [No Abstract]   [Full Text] [Related]  

  • 25. [Teprotumumab for the treatment of thyroid eye disease: The Holy grail, really?].
    Martel A
    J Fr Ophtalmol; 2023 Jun; 46(6):567-570. PubMed ID: 37068976
    [No Abstract]   [Full Text] [Related]  

  • 26. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
    Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
    Chern A; Dagi Glass LR; Gudis DA
    Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teprotumumab: The First Approved Biologic for Thyroid Eye Disease.
    Hwang CJ; Eftekhari K
    Int Ophthalmol Clin; 2021 Apr; 61(2):53-61. PubMed ID: 33743528
    [No Abstract]   [Full Text] [Related]  

  • 29. Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment.
    Ali F; Chorsiya A; Anjum V; Ali A
    Int Ophthalmol; 2021 Apr; 41(4):1549-1561. PubMed ID: 33481154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
    Smith TJ
    Front Endocrinol (Lausanne); 2020; 11():610337. PubMed ID: 33391187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
    Bartalena L; Marinò M; Marcocci C; Tanda ML
    J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
    [No Abstract]   [Full Text] [Related]  

  • 32. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The knowns and unknowns of teprotumumab for thyroid eye disease.
    Bednarczuk T; Pearce SH
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):323-325. PubMed ID: 33865499
    [No Abstract]   [Full Text] [Related]  

  • 34. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
    Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
    Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of teprotumumab in chronic, clinically active thyroid eye disease.
    Yu CY; Simmons BA; Pham CM; Shriver EM
    Eye (Lond); 2022 Jul; 36(7):1500-1501. PubMed ID: 34983925
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: "Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease".
    Kan AYL; Tiong CJ; Tsoi AT; Vasanthan A; Rezkalla M; Chan LJS; Francis IC
    Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):582-583. PubMed ID: 39240199
    [No Abstract]   [Full Text] [Related]  

  • 37. A Perspective on the Current Role of Teprotumumab in Treatment of Thyroid Eye Disease.
    Allen RC; Bradley EA; Fante RG; Lucarelli MJ
    Ophthalmology; 2021 Aug; 128(8):1125-1128. PubMed ID: 33823982
    [No Abstract]   [Full Text] [Related]  

  • 38. A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease.
    Douglas RS; Parunakian E; Tolentino J; Malkhasyan E; Geng J; Sherman M; Ugradar S
    Thyroid; 2024 Jan; 34(1):134-137. PubMed ID: 37962269
    [No Abstract]   [Full Text] [Related]  

  • 39. Reply Re: "Proptosis Regression After Teprotumumab Treatment for Thyroid Eye Disease".
    Rosenblatt TR; Chiou CA; Yoon MK; Wolkow N; Lee NG; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2024 Sep-Oct 01; 40(5):583. PubMed ID: 39240200
    [No Abstract]   [Full Text] [Related]  

  • 40. Teprotumumab-Induced Encephalopathy: A Rare Side Effect of a Novel Therapeutic.
    Yee MD; McCarthy J; Quinn B; Surani A
    WMJ; 2023 May; 122(2):134-137. PubMed ID: 37141481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.